Extracorporeal Photopheresis (ECP) has been recognised by the scientific community as a therapeutic option to treat various disorders, such as:
- Cutaneous T-cell lymphoma (Sezary syndrome)
- GVHD (acute and chronic)
- Solid organ transplant rejection
Macopharma has developed a complete product range for the off-line extracorporeal photpheresis technique.
Extracorporeal photopheresis (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (8-methoxypsoralen or 8-MOP) and UVA irradiation. Mononuclear cells are harvested by an apheresis device usually and reinfused to the patient after cell irradiation.